His primary scientific interests are in Internal medicine, Cardiology, Angioplasty, Surgery and Restenosis. His study in Coronary artery disease, Percutaneous coronary intervention, Conventional PCI, Randomized controlled trial and TIMI is done as part of Internal medicine. His Cardiology study integrates concerns from other disciplines, such as Stent and Coronary stent.
His work in Angioplasty tackles topics such as Stenosis which are related to areas like Randomization and Clinical trial. His biological study spans a wide range of topics, including Creatinine metabolism, Urology, Acute coronary syndrome and Intensive care medicine. His Restenosis study combines topics from a wide range of disciplines, such as Placebo, Percutaneous, Complication and Balloon.
His primary areas of investigation include Internal medicine, Cardiology, Myocardial infarction, Angioplasty and Surgery. His work on Coronary artery disease, Percutaneous coronary intervention and Perindopril as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. Many of his studies involve connections with topics such as Angiography and Cardiology.
The Myocardial infarction study combines topics in areas such as Randomized controlled trial and Ejection fraction. In his study, which falls under the umbrella issue of Angioplasty, Balloon, Complication and Percutaneous transluminal coronary angioplasty is strongly linked to Restenosis. His research integrates issues of Diabetes mellitus, Aspirin and Clinical trial in his study of Surgery.
Michel E. Bertrand focuses on Internal medicine, Cardiology, Myocardial infarction, Perindopril and Coronary artery disease. His Internal medicine research includes themes of Placebo and Surgery. In the subject of general Cardiology, his work in Percutaneous coronary intervention, Revascularization, TIMI and Angioplasty is often linked to In patient, thereby combining diverse domains of study.
His Angioplasty research is multidisciplinary, incorporating elements of Lesion and Atherectomy. His work is dedicated to discovering how Myocardial infarction, Stroke are connected with Proportional hazards model and other disciplines. The study incorporates disciplines such as Statin, Framingham Risk Score, Atorvastatin and Heart failure in addition to Coronary artery disease.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Coronary artery disease and Revascularization. His Internal medicine research focuses on Endocrinology and how it relates to Hazard ratio. His Myocardial infarction research incorporates themes from Stroke and Aldosterone.
His research on Coronary artery disease frequently connects to adjacent areas such as Angioplasty. His study in Angioplasty is interdisciplinary in nature, drawing from both Brain natriuretic peptide, Spironolactone, Ejection fraction and Heart failure. His Revascularization research includes elements of Ischemia and Percutaneous coronary intervention.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).
Lars Rydén;Eberhard Standl;Małgorzata Bartnik;Greet Van den Berghe.
European Heart Journal (2006)
Strategies for Multivessel Revascularization in Patients with Diabetes
Michael E. Farkouh;Michael Domanski;Lynn A. Sleeper;Flora S. Siami.
The New England Journal of Medicine (2012)
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).
Michel E. Bertrand;Hans-Jürgen Rupprecht;Philip Urban;Anthony H. Gershlick.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
E J Topol;D J Moliterno;H C Herrmann;E R Powers.
The New England Journal of Medicine (2001)
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
M. E. Bertrand;Victor Legrand;J. Boland;E. Fleck.
Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography.
M E Bertrand;J M LaBlanche;P Y Tilmant;F A Thieuleux.
Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology
M. E. Bertrand;M. L. Simoons;K. A. A. Fox;L. C. Wallentin.
European Heart Journal (2000)
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Gregg W Stone;Harvey D White;E Magnus Ohman;Michel E Bertrand.
The Lancet (2007)
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
Deepak L Bhatt;Michel E Bertrand;Peter B Berger;Philippe L L’Allier.
Journal of the American College of Cardiology (2002)
Apolipoprotein A-I containing lipoproteins in coronary artery disease
P. Puchois;A. Kandoussi;P. Fievet;J.L. Fourrier.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: